日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

inavolisib 单药及联合疗法在 PIK3CA 突变、HR 阳性、HER2 阴性晚期乳腺癌中的安全性概述及管理 (GO39374)

Gambardella, V; Accordino, M K; Bedard, P L; Cervantes, A; Hamilton, E; Italiano, A; Kalinsky, K; Krop, I E; Oliveira, M; Saura, C; Schmid, P; Turner, N C; Varga, A; Fernandez-Saranillo, A; Jin, Y; Royer-Joo, S; Peters, U; Shankar, N; Schutzman, J L; Juric, D; Jhaveri, K L

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis

真实世界中符合NATALEE和MonarchE入组条件的HR+/HER2-早期乳腺癌患者人群特征:一项基于美国电子健康记录数据库的分析

Tarantino, P; Rugo, H S; Curigliano, G; O'Shaughnessy, J A; Janni, W; Jhaveri, K; Mouabbi, J; Brufsky, A; Hamilton, E; O'Regan, R; Santarsiero, L; Akdere, M; Ye, F; Scotchmer, A; Graff, S L

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study

tiragolumab、atezolizumab 和化疗治疗早期或 PD-L1 阳性晚期三阴性乳腺癌的安全性和有效性:一项 Ib 期研究

Kuemmel, S; Jung, K H; Andrade, L; Assad-Suzuki, D; de la Cruz Merino, L; Freitas-Junior, R; Hegg, R; Huang, C-S; Martin, H; Schneeweiss, A; Dieterich, M; Nguyen Duc, A; Feng, Y; Meng, R; Swat, A; Seiller, A; Bermejo, B; Hamilton, E P

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

来自随机DESTINY-Breast03试验的曲妥珠单抗德鲁替康与曲妥珠单抗恩坦辛在HER2阳性脑转移性乳腺癌患者中的疗效比较

Hurvitz, S A; Kim, S-B; Chung, W-P; Im, S-A; Park, Y H; Hegg, R; Kim, M-H; Tseng, L-M; Petry, V; Chung, C-F; Iwata, H; Hamilton, E; Curigliano, G; Xu, B; Egorov, A; Liu, Y; Cathcart, J; Bako, E; Tecson, K; Verma, S; Cortés, J

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

taselisib (GDC-0032) 联合 HER2 靶向疗法治疗晚期 HER2 阳性乳腺癌患者的 Ib 期剂量递增试验

Grinshpun, A; Ren, S; Graham, N; DeMeo, M K; Wrabel, E; Carter, J; Tayob, N; Pereslete, A; Hamilton, E; Juric, D; Mayer, E L; Tolaney, S M; Krop, I E; Metzger, O

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

PF-06952229,一种选择性TGF-β-R1抑制剂:临床前开发和首次人体I期剂量递增研究(针对晚期实体瘤)

Yap, T A; Choudhury, A D; Hamilton, E; Rosen, L S; Stratton, K L; Gordon, M S; Schaer, D; Liu, L; Zhang, L; Mittapalli, R K; Zhong, W; Soman, N; Tolcher, A W

The relationship between spectral signals and retinal sensitivity in dendrobatid frogs

箭毒蛙光谱信号与视网膜敏感度的关系

Walkowski, Whitney G; Richards-Zawacki, Corinne L; Gordon, William C; Bazan, Nicolas G; Farris, Hamilton E

Tuned in to communication sounds: Neuronal sensitivity in the túngara frog midbrain to frequency modulated signals

对交流声音的敏锐感知:通加拉蛙中脑神经元对频率调制信号的敏感性

Ponnath, Abhilash; Ryan, Michael J; Fang, Zhide; Farris, Hamilton E

Latent TGFβ-binding proteins regulate UCP1 expression and function via TGFβ2

潜在 TGFβ 结合蛋白通过 TGFβ2 调节 UCP1 表达和功能

D Halbgebauer, J Roos, J B Funcke, H Neubauer, B S Hamilton, E Simon, E Z Amri, K M Debatin, M Wabitsch, P Fischer-Posovszky, D Tews

Estrogenic Modulation of Retinal Sensitivity in Reproductive Female Túngara Frogs

雌激素对生殖期雌性通加拉蛙视网膜敏感性的调节

Leslie, Caitlin E; Walkowski, Whitney; Rosencrans, Robert F; Gordon, William C; Bazan, Nicolas G; Ryan, Michael J; Farris, Hamilton E